200,000+ products from a single source!

sales@angenechem.com

Home > Oxazole > 350992-10-8

350992-10-8

350992-10-8 | 7-[4-[(3-PHENYLPHENYL)METHYL]PIPERAZIN-1-YL]-3H-BENZO[D]OXAZOL-2-ONE

CAS No: 350992-10-8 Catalog No: AG007FYK MDL No:

Product Description

Catalog Number:
AG007FYK
Chemical Name:
7-[4-[(3-PHENYLPHENYL)METHYL]PIPERAZIN-1-YL]-3H-BENZO[D]OXAZOL-2-ONE
CAS Number:
350992-10-8
Molecular Formula:
C24H23N3O2
Molecular Weight:
385.4583
IUPAC Name:
7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
InChI:
InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
InChI Key:
CYGODHVAJQTCBG-UHFFFAOYSA-N
SMILES:
O=c1[nH]c2c(o1)c(ccc2)N1CCN(CC1)Cc1cccc(c1)c1ccccc1
UNII:
AP69E83Z79

Properties

Complexity:
556  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
385.179g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
385.467g/mol
Monoisotopic Mass:
385.179g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
44.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.2  

Literature

Title Journal
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands. Journal of medicinal chemistry 20140710
Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. Addiction biology 20120301
Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology 20120201
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120201
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology 20111015
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. The international journal of neuropsychopharmacology 20111001
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 20110801
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. Journal of medicinal chemistry 20110714
Newer molecules in the treatment of schizophrenia: A clinical update. Indian journal of pharmacology 20110401
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC psychiatry 20110101
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PloS one 20110101
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. The Journal of clinical psychiatry 20101001
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Current opinion in investigational drugs (London, England : 2000) 20100701
Development and application of an LC-MS/MS method for measuring the effect of (partial) agonists on cAMP accumulation in vitro. Journal of neuroscience methods 20100430
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). Journal of medicinal chemistry 20100325
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic & medicinal chemistry 20100301
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Current opinion in pharmacology 20100201
Tetrabenazine is neuroprotective in Huntington's disease mice. Molecular neurodegeneration 20100101
Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatric disease and treatment 20100101
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. Behavioural brain research 20091105
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neuroscience letters 20090821
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European journal of pharmacology 20090401
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. Journal of psychopharmacology (Oxford, England) 20090301
Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. Synapse (New York, N.Y.) 20081201
Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds. European journal of pharmacology 20081112
Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European journal of pharmacology 20081112
Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 20081101
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology 20081001
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. European journal of pharmacology 20080911
Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. European journal of pharmacology 20080707
Bipolar depression: trial-based insights to guide patient care. Dialogues in clinical neuroscience 20080601
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. The international journal of neuropsychopharmacology 20080501
Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behavioural pharmacology 20080301
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. European journal of pharmacology 20080226
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular psychiatry 20080101
Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. Parkinsonism & related disorders 20080101
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 20080101
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European journal of pharmacology 20071128
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn-Schmiedeberg's archives of pharmacology 20071001
Pharmacological causes of hyperprolactinemia. Therapeutics and clinical risk management 20071001
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. Journal of neurochemistry 20070801
Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology 20070801
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology 20070701
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Current opinion in investigational drugs (London, England : 2000) 20070701
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology 20070401
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 20070301
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural pharmacology 20070301
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. Journal of medicinal chemistry 20070222
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacology bulletin 20070101
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060901
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedeberg's archives of pharmacology 20060901
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. European journal of pharmacology 20060327
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. European journal of pharmacology 20060318
Aripiprazole: the evidence of its therapeutic impact in schizophrenia. Core evidence 20060101
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. The Journal of pharmacology and experimental therapeutics 20051001
Molecule of the month. Bifeprunox mesilate. Drug news & perspectives 20051001
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. The international journal of neuropsychopharmacology 20050901
Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 20050801
DU-127090 Solvay/H Lundbeck. Current opinion in investigational drugs (London, England : 2000) 20030101
New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorganic & medicinal chemistry letters 20010903

Related Products

© 2019 Angene International Limited. All rights Reserved.